Accuracy in melanoma detection: A 10-year multicenter survey
Giuseppe Argenziano(Regione Campania), Harald Kittler(Medical University of Vienna), Rainer Hofmann‐Wellenhof(Medical University of Graz), David Langford, Massimo Mascolo(University of Naples Federico II), William V. Stoecker(University of Missouri Health System), Stefania Staibano(University of Naples Federico II), Laura Mazzoni(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Cesare Massone(Medical University of Graz), Philipp Tschandl(Simon Fraser University), Gerardo Ferrara(Azienda Ospedaliera G.Rummo), Akane Minagawa(Ōtani University), Akira Ishiko(Toho University), David Calcara(Dermatology Research Center), Hiroshi Koga(Ōtani University), Masaru Tanaka, Ignazio Stanganelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Scott W. Menzies(Royal Prince Alfred Hospital), Ana Carolina de Carvalho(The University of Sydney), Gülşen Kandiloğlu(Ege University), Hiroshi Kawasaki(Keio University), Blanca Carlos‐Ortega(Universidad Nacional Autónoma de México), Katherine Siamas(Memorial Sloan Kettering Cancer Center), Fezal Özdemir(Ege University), Renato Marchiori Bakos(Universidade Federal do Rio Grande do Sul), Roberto Bandelloni(Ente Ospedaliero Ospedali Galliera), Lorenzo Cerroni(Medical University of Graz), Nicola Arpaia(University of Bari Aldo Moro), Jadran Bandić, L. Thomas(University of Liverpool), Raffaele Filotico(University of Bari Aldo Moro), Huiting Dong(Zhengzhou University), Alexandra Maria Giovanna Brunasso(Ente Ospedaliero Ospedali Galliera), Loredana Nugnes(University of Naples Federico II), Iris Zalaudek(Azienda Sanitaria Universitaria Integrata di Trieste), Gennaro Ilardi(University of Naples Federico II), Ivanka Kovalyshyn(Memorial Sloan Kettering Cancer Center), Ashfaq A. Marghoob(Memorial Sloan Kettering Cancer Center), Xin Liu, G. Esparza Gómez(Universidad Nacional Autónoma de México), Ken Kobayashi(Tokyo Women's Medical University), Gabriel Casas(Hospital Alemán), Stefania Seidenari(University of Modena and Reggio Emilia), Horacio Cabo, Giovanni Pellacani(Sapienza University of Rome), B. Balme(Université Claude Bernard Lyon 1), Allan C. Halpern(Memorial Sloan Kettering Cancer Center)
Cited by 206
Related Papers
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2016|1k
Skin Lesion Analysis Toward Melanoma Detection 2018: A Challenge Hosted by the International Skin Imaging Collaboration (ISIC)
|arXiv (Cornell University)|2019|990
Germline mutations in BAP1 predispose to melanocytic tumors
|Nature Genetics|2011|724